Key clinical point: For patients with previously untreated malignant pleural mesothelioma (MPM), adding tumor treating fields (TTFields) to standard chemotherapy could boost median overall survival by about 6 months, with greatest benefit among patients with epithelioid MPM.

Major finding: Patients with MPM who were treated with TTFields in combination with pemetrexed and cisplatin or carboplatin had a median overall survival (OS) of 18.2 months, compared with the historical median OS of 12.1 months for patients receiving only standard first-line therapy, pemetrexed with cisplatin.

Study details: STELLAR was a phase 2 trial involving 80 patients with mesothelioma.

Disclosures: Dr. Ceresoli disclosed travel funding from Novocure.